Back to results
US 2013/0281376 A1Published application
Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
AssigneeAbraxis BioScience, LLC
InventorsVuong Trieu, Larn Hwang, Kouros Motamed, Xiping Liu, Neil Desai
Life of this patent
Estimating the term…
Abstract
The invention provides multiparametric anti-SPARC antibody-based techniques for treating cancers as well as determining prognosis and predicting the response to therapy, including chemotherapy, radiotherapy, surgical therapy and combination therapies.
Claims40
A method of treating a tumor in a mammal with a chemotherapeutic regimen comprising:
- (a) determining a SPARC microenvironment signature (SMS) of the mammal, wherein the SMS is then compared to a predefined SMS;
- (b) quantifying plasma SPARC in the mammal;
- and
- (c) quantifying plasma lactate dehydrogenase (LDH) in the mammal;
- and
- (d) administering a therapeutically effective amount of the chemotherapeutic regimen if two or more of the following conditions is met:
- SMS satisfies the criteria of a predetermined SMS, circulating SPARC is elevated as compared to a negative control, and plasma LDH is elevated as compared to a negative control.
4 more elements
A method of predicting a response to a chemotherapeutic regimen in a mammal comprising:
- (a) determining a SPARC microenvironment signature (SMS) of the mammal, wherein the SMS is then compared to a predefined SMS;
- (b) quantifying plasma SPARC in the mammal;
- and
- (c) quantifying plasma lactate dehydrogenase (LDH) in the mammal,
- wherein a positive response to the chemotherapeutic regimen is predicted if two or more of the following conditions are met:
- SMS satisfies the criteria of a low-risk SMS, circulating SPARC is not elevated as compared to a negative control, and plasma LDH is not elevated as compared to a negative control;
- and a negative response to the chemotherapeutic regimen is predicted if two or more of the following conditions are met:
- SMS satisfies the criteria of a high-risk SMS, circulating SPARC is elevated as compared to a negative control, and plasma LDH is elevated as compared to a negative control.
5 more elements
A method of determining a prognosis of a tumor in a mammal comprising:
- (a) determining a SPARC microenvironment signature (SMS) of the mammal, wherein the SMS is then compared to a predefined SMS;
- (b) quantifying plasma SPARC in the mammal;
- and
- (c) quantifying plasma lactate dehydrogenase (LDH) in the mammal,
- wherein a positive prognosis is determined if two or more of the following conditions are met:
- SMS satisfies the criteria of a low-risk SMS, circulating SPARC is not elevated as compared to a negative control, and plasma LDH is not elevated as compared to a negative control;
- and a negative prognosis is determined if two or more of the following conditions are met:
- SMS satisfies the criteria of a high-risk SMS, circulating SPARC is elevated as compared to a negative control, and plasma LDH is elevated as compared to a negative control.
5 more elements
A method of treating a metastatic cancer in a mammal with a chemotherapeutic regimen comprising:
- (a) determining a SPARC microenvironment signature (SMS) of the mammal's primary tumor,
- (b) determining a SMS of a metastatic tumor from said primary tumor in the same mammal,
- (b) determining if the SMS of the metastatic tumor is sufficiently similarity to the SMS of the primary tumor;
- and
- (c) administering a therapeutically effective amount of the chemotherapeutic regimen if the if the SMS of the metastatic tumor sample is sufficiently similar to the SMS of the primary tumor sample.
2 more elements
A method of treating a tumor in a mammal with a chemotherapeutic regimen comprising:
- (a) determining a SPARC microenvironment signature (SMS) of the mammal's primary tumor and a SMS of a metastatic tumor from said primary tumor in said mammal;
- (b) quantifying plasma SPARC in the mammal;
- and
- (c) quantifying plasma lactate dehydrogenase (LDH) in the mammal;
- and
- (d) administering a therapeutically effective amount of the chemotherapeutic regimen if two or more of the following conditions is met:
- the SMS of a primary tumor is sufficiently similar to the SMS of the metastatic tumor;
- plasma SPARC is not elevated as compared to a negative control, and plasma LDH is not elevated as compared to a negative control.
5 more elements
A method of predicting a response to a chemotherapeutic regimen in a mammal comprising:
- (a) determining a SPARC microenvironment signature (SMS) of the mammal's primary tumor and a SMS of a metastatic tumor from said primary tumor in said mammal;
- (b) quantifying plasma SPARC in the mammal;
- and
- (c) quantifying plasma lactate dehydrogenase (LDH) in the mammal,
- wherein a positive response to the chemotherapeutic regimen is predicted if two or more of the following conditions are met:
- the SMS of a primary tumor is sufficiently similar to the SMS of the metastatic tumor;
- plasma SPARC is not elevated as compared to a negative control, plasma LDH is not elevated as compared to a negative control;
- and a negative response to the chemotherapeutic regimen is predicted if two or more of the following conditions are met:
- the SMS of a primary tumor is not sufficiently similar to the SMS of the metastatic tumor, plasma SPARC is elevated as compared to a negative control, and plasma LDH is elevated as compared to a negative control.
6 more elements
A method of determining a prognosis of a tumor in a mammal comprising:
- (a) determining a SPARC microenvironment signature (SMS) of the mammal's primary tumor and a SMS of a metastatic tumor from said primary tumor in said mammal;
- (b) quantifying plasma SPARC in the mammal;
- and
- (c) quantifying plasma lactate dehydrogenase (LDH) in the mammal,
- wherein a positive prognosis is determined if two or more of the following conditions are met:
- the SMS of a primary tumor is sufficiently similar to the SMS of the metastatic tumor, plasma SPARC is not elevated as compared to a negative control, and plasma LDH is not elevated as compared to a negative control;
- and a negative prognosis is determined if two or more of the following conditions are met:
- the SMS of a primary tumor is not sufficiently similar to the SMS of the metastatic tumor;
- plasma SPARC is elevated as compared to a negative control, and plasma LDH is elevated as compared to a negative control.
6 more elements
Dependencies are inferred from the claim text.